Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728934 · ClinicalTrials.gov registry record
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
A clinical trial, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- 1,279
- Enrollment target
NCT02728934 is a clinical trial that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 1,279 participants.
The verdict
NCT02728934 has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- 1,279 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the proportion of patients with an infusion reaction in Rheumatoid arthritis (RA) patients treated with Golimumab Intravenous (IV) or Infliximab.
Interventions
- BIOLOGICAL Infliximab
- BIOLOGICAL Golimumab Intravenous (IV)
- BIOLOGICAL Biosimilar Infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,279 participants |
| Start Date | 2016-02-25 |
| Est. Completion | 2020-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02728934
The ClinicalTrials.gov registry entry for NCT02728934 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Infliximab is the first listed.
NCT02728934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02728934 about?
NCT02728934 is a clinical study titled "Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis". The purpose of this study is to compare the proportion of patients with an infusion reaction in Rheumatoid arthritis (RA) patients treated with Golimumab Intravenous (IV) or Infliximab.
What is the current status of trial NCT02728934?
This trial is currently completed. The enrollment target is 1,279 participants. The study started on 2016-02-25. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT02728934?
The interventions under investigation include: Infliximab (BIOLOGICAL), Golimumab Intravenous (IV) (BIOLOGICAL), Biosimilar Infliximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02728934?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.